Inactive Instrument
Irwin Naturals Inc. Stock Canadian Securities Exchange
Stocks
IWIN
CA46414Q1054
Pharmaceuticals
OTC Markets Traded| Market Cap | 483K 420K 392K 360K 678K 46.04M 690K 4.62M 1.81M 22.96M 1.81M 1.77M 75.72M | P/E 2021 |
105x | P/E 2022 | -0.91x |
|---|---|---|---|---|---|
| Enterprise Value | 21.01M 18.26M 17.05M 15.65M 29.51M 2B 30.02M 201M 78.73M 999M 78.92M 77.17M 3.29B | EV / Sales 2021 |
0.13x | EV / Sales 2022 | 0.31x |
| Free-Float |
1.04% | Yield 2021 * |
-
| Yield 2022 | - |
| 3 years | 0.05 | 1.5 | |
| 5 years | 0.05 | 4.75 | |
| 10 years | 0.05 | 4.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Klee Irwin
CEO | Chief Executive Officer | 60 | 1993-12-31 |
Mark Green
DFI | Director of Finance/CFO | - | 2024-03-07 |
| Director | Title | Age | Since |
|---|---|---|---|
Klee Irwin
CHM | Chairman | 60 | 1993-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/16/21 | Other | Chief Executive Officer | 0 | - | ||
| 8/16/21 | Other | Chief Executive Officer | 0 | - | ||
| 8/16/21 | Marche | Chief Executive Officer | 18,240 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | - | - | 708K | ||
| -2.83% | -6.82% | +45.11% | +148.43% | 1,024B | ||
| -1.50% | -4.99% | +47.73% | +48.08% | 618B | ||
| -2.22% | -4.33% | +24.65% | +64.91% | 443B | ||
| +0.68% | -1.14% | +39.61% | +33.36% | 349B | ||
| -1.66% | -3.13% | +31.63% | +39.79% | 297B | ||
| -8.96% | -10.77% | +3.27% | +5.50% | 264B | ||
| -1.37% | -7.41% | -3.42% | -43.67% | 209B | ||
| -1.95% | +0.81% | +25.62% | +64.41% | 208B | ||
| -0.61% | -0.48% | +13.44% | +71.98% | 162B | ||
| Average | -1.88% | -1.35% | +25.29% | +48.09% | 397.08B | |
| Weighted average by Cap. | -2.09% | -2.17% | +32.88% | +70.34% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 100M 87.21M 81.42M 74.74M 141M 9.56B 143M 960M 376M 4.77B 377M 369M 15.73B | 89.47M 77.76M 72.6M 66.64M 126M 8.53B 128M 856M 335M 4.25B 336M 329M 14.03B |
| Net income | 8.62M 7.49M 6.99M 6.42M 12.1M 821M 12.31M 82.42M 32.28M 409M 32.36M 31.64M 1.35B | -3.99M -3.47M -3.24M -2.97M -5.61M -381M -5.7M -38.19M -14.96M -190M -14.99M -14.66M -626M |
| Net Debt | 9.35M 8.13M 7.59M 6.97M 13.14M 891M 13.37M 89.48M 35.05M 445M 35.13M 34.35M 1.47B | 20.53M 17.84M 16.66M 15.29M 28.83M 1.96B 29.33M 196M 76.92M 976M 77.11M 75.4M 3.22B |
Employees
-
Sector
Pharmaceuticals
















